Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
Metrics to compare | 2629 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2629PeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.3x | −3.5x | −0.5x | |
PEG Ratio | - | −0.05 | 0.00 | |
Price/Book | 5.3x | 3.8x | 2.6x | |
Price / LTM Sales | 26.2x | 24.8x | 3.2x | |
Upside (Analyst Target) | - | 198.6% | 51.4% | |
Fair Value Upside | Unlock | 0.0% | 7.1% | Unlock |